The Food and Drug Administration (FDA) said it is conducting an ongoing investigation to determine the scope of the issue and assess any potential safety implications following the voluntary recall of select infant formula products by Nestlé Philippines.

In a statement released on Monday, Jan. 12, the FDA said it is actively overseeing and validating the recall involving specific batches of NAN OPTIPRO and NANKID OPTIPRO infant formula products, which was initiated as a precautionary measure.

“The FDA is conducting an ongoing investigation to determine the scope of the issue and to assess any potential safety implications,” the agency stated.

The agency said the recall followed a reported incident involving a raw material from the manufacturer’s supplier.

“The voluntary recall follows a reported incident involving a raw material from the manufacturer’s supplier. At present, there are no established food safety or regulatory limits on the raw material identified.”

In coordination with the manufacturer, the FDA said it is verifying affected batches and ensuring recalled products are promptly removed from both physical and online retail outlets.

“In close coordination with the manufacturer, the FDA is verifying the specific affected batches, ensuring the prompt and complete removal of recalled products from physical and online retail outlets, and conducting distribution and communication checks to confirm that recall measures are effectively implemented across the supply chain.”

The FDA said no illnesses or adverse events linked to the recalled products have been reported so far.

“At this time, the FDA has not received any reports of illness or adverse events associated with the recalled products.”

Despite this, the agency said it fully supports the precautionary recall, particularly to protect infants and young children.

“While no adverse events have been reported, the FDA fully supports this precautionary action to protect public health, especially infants and young children.”

The FDA advised consumers to check product batch numbers and comply with recall instructions issued by the manufacturer.

“The FDA advises consumers to carefully check product batch numbers, immediately discontinue use of any affected products, and strictly follow the recall instructions issued by the manufacturer.”

It added that an official advisory will be issued to provide further guidance to the public.

Meanwhile, the agency said it will continue post-market surveillance and inspections to ensure product safety and quality.

“The FDA will continue to carry out post-market surveillance, inspections, and product assessments to ensure that all regulated products in the market meet established safety and quality requirements,” it said.

The FDA reiterated its commitment to transparency and consumer protection.

“The FDA remains steadfast in fulfilling its mandate to protect public health and to ensure that all regulated health products available to consumers are safe, of good quality, and compliant with applicable laws and regulations.”